News

Mauna Kea Technologies reports full financial results for first half of 2020 and preliminary third quarter of 2020 sales

22 September 2020

1H’20 financial results driven primarily by a 10% reduction in total operating expenses (without COGS) and a 17% reduction in net loss compared to prior year period 
Preliminary Third Quarter Total Sales Increase 2% to 11% year-over-year; U.S. Sales up 1% to 3% 

Mauna Kea Technologies today announced full financial results for the first half of 2020 ended June 30, 2020 and its preliminary sales for the third quarter. Given the significant uncertainties associated with pace of recovery from the COVID-19 pandemic, the Company has elected to provide, in this context, specific information on current-quarter expected revenue trends.

Latest News

Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 

PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

No results found.